GlassScriptPhysician profile
Garth A Ashbeck
NPI 1710972781
$4,016.43
in general payments reported to CMS, 2019-2025
36 companies · $925 in 2025
The $925 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $80.09 · 2021: $285 · 2022: $501 · 2023: $702 · 2024: $681 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,308.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $453.99 | 2019-2025 | Verquvo, Gardasil 9, Belsomra |
| Novo Nordisk INC | $430.47 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $363.02 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Pfizer INC. | $313.38 | 2019-2025 | |
| Abbvie INC. | $301.98 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $282.83 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $249.81 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $177.43 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $176.08 | 2024-2025 | Veozah |
| Abbott Laboratories | $163.81 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $116.29 | 2019-2025 | Evenity, Prolia, Repatha |
| Lundbeck LLC | $108.92 | 2022-2025 | Vyepti, Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.01 | 2021-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $68.92 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $65.65 | 2022-2023 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garth Ashbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.